Dyne Submits IND Application to Initiate Trial for Duchenne Therapy

 - DYNE-251, Dyne’s First DMD Program, is Being Developed for Patients with Mutations Amenable to Skipping Exon 51 -

- DYNE-101 IND Submission in DM1 Expected in the First Quarter of 2022 -

- Initiation of Patient Dosing of DYNE-251 and DYNE-101 in Multiple Ascending Dose Clinical Trials Anticipated by Mid-2022 -

https://finance.yahoo.com/news/dyne-therapeutics-announces-submission-ind-133000648.html